FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:1560-1561 May 27, 1993 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Rarely has an important scientific advance been the subject of as much political, ideological, and social controversy as mifepristone (RU 486). The development of a safe and effective antiprogestin compound had been the goal of researchers in the field of reproductive biology for decades. The pioneering work of scientists at Roussel-UCLAF in France led to the approval of mifepristone by the French Ministry of Solidarity, Health, and Social Welfare in September 1988^1,2. The use of mifepristone, coupled with a prostaglandin and administered within 49 days of the last menstrual period, produces a complete abortion in approximately 95 percent of . . . [Full Text of this Article]

References

This article has been cited by other articles:

• de Ziegler, D. (2003). Associate editor's commentary: The dawning of the non-cancer uses of aromatase inhibitors in gynaecology. Hum Reprod 18: 1598-1602 [Full Text]  
• Christin-Maitre, S., Bouchard, P., Spitz, I. M. (2000). Medical Termination of Pregnancy. NEJM 342: 946-956 [Full Text]  
• (1993). AN EFFECTIVE ORAL REGIMEN FOR EARLY PREGNANCY TERMINATION. JWatch General 1993: 2-2 [Full Text]